Serum infliximab levels and clinical response in hidradenitis suppurativa

• Príomhchruthaitheoirí: Erwin Benassaia (Údar), Jean‐David Bouaziz (Údar), Marie Jachiet (Údar), Florence Cordoliani (Údar), Anne Saussine (Údar), Clemence Lepelletier (Údar), Lauriane Goldwirt (Údar), Charles Cassius (Údar), Adèle deMasson (Údar), Martine Bagot (Údar), Hervé Bachelez (Údar), Florence Assan (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Wiley, 2023-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Background Infliximab (IFX) is a chimeric immunoglobulin G‐1κ monoclonal antibody that neutralises the biologic activity of tumour necrosis factor‐α, and has shown efficacy (off‐label) for the treatment of severe hidradenitis suppurativa (HS). The relationship between clinical response and...